D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00780442|
Recruitment Status : Completed
First Posted : October 27, 2008
Results First Posted : July 6, 2018
Last Update Posted : July 6, 2018
|Condition or disease||Intervention/treatment||Phase|
|Cocaine Use Disorders||Drug: D-cycloserine Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||27 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals|
|Study Start Date :||September 2006|
|Actual Primary Completion Date :||July 2008|
|Actual Study Completion Date :||July 2008|
D-Cycloserine 50 mg is a partial glutamate agonist. Participants received DCS prior to cocaine cue exposure sessions.
50 mg DCS
Placebo Comparator: Placebo
Saline comparator. Participants received placebo prior to cocaine cue exposure sessions.
- Cocaine Craving Scale [ Time Frame: Immediately following cue exposure ]Scale assess cocaine craving following cocaine cue exposure after two administrations of DCS. Subjects rate craving on a scale from 0-10 with 0 indicating "Not at all" and 10 indicating "Extremely".
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00780442
|United States, South Carolina|
|Medical University of South Carolina|
|Charleston, South Carolina, United States, 29425|
|Principal Investigator:||Aimee L McRae, Pharm.D.||Medical University of South Carolina|